Table 2 Baseline characteristics of the study cohort
Variable | All patients (n = 103) |
|---|---|
Median age, years (IQR) | 69 (65–76) |
Sex, n (%) | |
Female | 16 (15.5) |
Male | 87 (84.5) |
Etiology, n (%) | |
Alcohol | 55 (53.4) |
Hepatitis B | 13 (12.6) |
Hepatitis C | 5 (4.9) |
NASH | 9 (8.7) |
Hemochromatosis | 3 (2.9) |
AIH/PBC/PSC | 4 (3.9) |
Unknown/Other | 14 (13.6) |
Child-Pugh stage, n (%) | |
A | 44 (42.7) |
B | 41 (39.8) |
C | 7 (6.8) |
No cirrhosis | 11 (10.7) |
BCLC stage, n (%) | |
0 | 0 |
A | 25 (24.3) |
B | 65 (63.1) |
C | 6 (5.8) |
D | 7 (6.8) |
Median tumor size of the largest lesion, mm (IQR) | 42 (30–60) |
Tumor number, n (%) | |
Unifocal | 19 (18.5) |
Multifocal | 80 (77.7) |
Diffuse growth pattern | 4 (3.8) |
Laboratory parameters, median (IQR) | |
Albumin, g/L | 31 (28–36) |
Bilirubin, mg/dl | 1.44 (0.92–2.5) |
Platelet count, per mm3 | 111 (74–172) |
AST, U/l | 61 (42–88) |
ALT, U/l | 40 (25–59) |
INR | 1.2 (1.1–1.3) |
AFP, U/l | 25 (6–280) |
Type of TACE, n (%) | |
cTACE | 29 (28.2) |
DEB-TACE | 74 (71.8) |